-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Acetazolamide + Dronabinol) in Obstructive Sleep Apnea
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Acetazolamide + Dronabinol) in Obstructive Sleep Apnea report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Acetazolamide + Dronabinol) in Obstructive Sleep Apnea Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Annamycin in Relapsed Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Annamycin in Relapsed Acute Myeloid Leukemia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Annamycin in Relapsed Acute Myeloid Leukemia Drug Details: L-Annamycin...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Mipasetamab Uzoptirine in Malignant Fibrous Histiocytoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Mipasetamab Uzoptirine in Malignant Fibrous Histiocytoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Mipasetamab Uzoptirine in Malignant Fibrous Histiocytoma Drug Details: ADCT-601(BGB-601)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Cannabidiol + Hydroxychloroquine) in Rheumatoid Arthritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Cannabidiol + Hydroxychloroquine) in Rheumatoid Arthritis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Cannabidiol + Hydroxychloroquine) in Rheumatoid Arthritis Drug Details: IHL-675A, a...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Cannabidiol + Hydroxychloroquine) in Inflammatory Bowel Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Cannabidiol + Hydroxychloroquine) in Inflammatory Bowel Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Cannabidiol + Hydroxychloroquine) in Inflammatory Bowel Disease Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Cannabidiol + Hydroxychloroquine) in Lung Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Cannabidiol + Hydroxychloroquine) in Lung Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Cannabidiol + Hydroxychloroquine) in Lung Disease Drug Details: IHL-675A, a...
-
Product Insights
NewOpium (Opioid) Addiction – Drugs In Development, 2024
Empower your strategies with our Opium (Opioid) Addiction – Drugs In Development, 2024 report and make more profitable business decisions. Opioid addiction develops after using opioids regularly for a period of time. Prolonged use of opiates can lead to nerve damage within the brain that causes cells to stop producing endogenous opiates (natural painkillers, known as endorphins). This can lead to an inability of the body to stop pain, because there are no endorphins to mask the pain initially. The degeneration...
-
Product Insights
NewChemotherapy Induced Nausea and Vomiting – Drugs In Development, 2024
Empower your strategies with our Chemotherapy Induced Nausea and Vomiting – Drugs In Development, 2024 report and make more profitable business decisions. Chemotherapy-induced nausea and vomiting (CINV) is nausea and vomiting that results specifically from treatment with chemotherapy drugs. Other symptoms include a rapid heart rate, sweating, dizziness, and increased saliva. Risk factors include age, drug, dose, and the schedule and route of the drug's administration. The Chemotherapy Induced Nausea and Vomiting drugs in development market research report provide comprehensive information...
-
Product Insights
NewGeneralized Anxiety Disorder (GAD) – Drugs In Development, 2024
Empower your strategies with our Generalized Anxiety Disorder (GAD) – Drugs In Development, 2024 report and make more profitable business decisions. Generalized anxiety disorder is a mental health disorder that produces fear, worry, and a constant feeling of being overwhelmed. It is characterized by excessive, persistent, and unrealistic worry about everyday things. Individuals with GAD typically experience heightened anxiety and apprehension, anticipating negative outcomes in everyday situations. Physical symptoms may include restlessness, muscle tension, fatigue, and difficulty concentrating. Unlike specific phobias...
-
Product Insights
NewObstructive Sleep Apnea – Drugs In Development, 2024
Empower your strategies with our Obstructive Sleep Apnea – Drugs In Development, 2024 report and make more profitable business decisions. Obstructive sleep apnea (OSA) is defined by episodes of either complete collapse or partial collapse of the airway during sleep, accompanied by a reduction in oxygen saturation or awakening from sleep. This disruption leads to fragmented and nonrestorative sleep. The implications of OSA extend to various aspects of health, including cardiovascular well-being, mental health, overall quality of life, and safety while...